XML 98 R69.htm IDEA: XBRL DOCUMENT v3.20.4
Information by segment and main country - Information on income statements (Detail) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Information by segment and main country [Line Items]      
Revenue € 19,535 € 19,482 € 18,121
Sales including intercompany 19,535 19,482 18,121
Depreciation and amortisation expense 1,520 [1] 1,402 [2] 1,089 [2]
Adjusted EBITA [3] 2,570 2,563 2,366
Diagnosis & Treatment [Member]      
Information by segment and main country [Line Items]      
Revenue 8,175 [4] 8,485 7,726
Sales including intercompany 8,289 [4] 8,576 7,806
Depreciation and amortisation expense 536 [4] 564 349
Adjusted EBITA [3] 816 [4] 1,078 872
Connected Care [Member]      
Information by segment and main country [Line Items]      
Revenue 5,564 4,674 4,341
Sales including intercompany 5,640 4,705 4,358
Depreciation and amortisation expense 415 327 326
Adjusted EBITA [3] 1,195 618 662
Personal Health [Member]      
Information by segment and main country [Line Items]      
Revenue 5,407 5,854 5,524
Sales including intercompany 5,424 5,864 5,538
Depreciation and amortisation expense 187 186 171
Adjusted EBITA [3] 704 943 860
Other [Member]      
Information by segment and main country [Line Items]      
Revenue 389 469 530
Sales including intercompany 463 542 612
Depreciation and amortisation expense 382 326 244
Adjusted EBITA [3] (145) (76) (28)
Intersector Eliminations [member]      
Information by segment and main country [Line Items]      
Sales including intercompany € (281) € (204) € (193)
[1] Includes impairments; for impairment values please refer to Property, plant and equipment and Intangible assets excluding goodwill
[2] Includes impairments; for impairment values please refer to Property, plant and equipment and Intangible assets excluding goodwill
[3] Non-IFRS financial measure. For the definition and reconciliation of the most directly comparable IFRS measure, refer to Reconciliation of non-IFRS information.
[4] In 2019 Philips’ Emerging Businesses were moved out of segment Other into segment Diagnosis & Treatment to enable these businesses with better access to downstream capabilities. While these businesses remain in (semi-)incubator phase, in 2020 they received a corporate funding out of segment Other of EUR 38 million (2019: EUR 54 million) to support them during their emerging idea-to-market business phase.